21829-13-0

Basic information

• Product Name: 4-(4-Amino-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester
• CAS NO: 21829-13-0
• Molecular Weight: 316.357
• Mol File: 21829-13-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(4-Amino-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Amino-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester(21829-13-0)
• EPA Substance Registry System: 4-(4-Amino-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester(21829-13-0)

Safety Data

• Hazardous Substances Data: 21829-13-0(Hazardous Substances Data)

Upstream product

• 105-45-3 acetoacetic acid methyl ester 
• 21829-09-4 4-(4-nitrophenyl)-2,6-dimethyl-3,5-dimethoxycarbonyl-1,4-dihydropyridine 
• 555-16-8 4-nitrobenzaldehdye 

Relevant articles and documents

Synthesis and pharmacological evaluation of novel homocamptothecin- dihydropyridine derivative conjugates as potent topoisomerase i inhibitors

Homocamptothecins (hCPT) represent a new generation of antitumour agents targeting DNA topoisomerase I. The expanded seven-membered lactone E-ring that characterizes hCPT enhances the plasma stability of the drug and reinforces the inhibition of topoisomerase I (Topo I) compared with conventional six-membered CPT. In an attempt to improve the antitumour activity of hCP, a series of novel hCPT derivatives conjugating with dihydropyridine derivates were designed and synthesized based on a synthetic route that couples 7-formylhomocamptothecin with different dihydropyridine derivates. Most of the synthesized compounds exhibited good cytotoxic activity on tumour cell line A549, MDA-MB-435, and HCT116. Furthermore, this class of compounds showed superior Topo I inhibition activity comparable to or higher than CPT. CSIRO 2011.